Fecal Transplant for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Fecal Transplant for Health & Longevity

Created on 07/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Fecal transplant rebuilds a disrupted gut microbial community using screened donor stool. It is well proven for a stubborn, recurring gut infection, where it works when standard medicines fail. Benefits for bowel inflammation, metabolic health, liver disease, and aging are promising but unsettled. Short-term safety is reasonably good; rare serious infections occur, and long-term effects are unknown. (Full Review)

Protocol

Standard Course
Single infusion
For recurrent infection, after a short antibiotic course and, for lower-gut routes, bowel preparation
Approved Products
Rectal 150 mL or oral capsules
Oral product: four capsules once daily for three days after bowel preparation
Delivery Route
Colonoscopy, enema, capsule, or tube
Choice balances efficacy, invasiveness, and convenience; intensive repeated dosing for bowel disease
Time to effect
Infection Resolution
Days–2 weeks
Resolution of recurrent gut infection is often rapid
Inflammatory / Metabolic
Weeks
Metabolic or inflammatory effects, where they occur, unfold over weeks
Engraftment
Months
Persistence of the transplanted community is assessed over months

Benefits

Contraindications
  • Severe immunocompromise (neutrophil count <500/µL, active high-dose immunosuppression, recent bone-marrow transplant)
  • Unstable or critically ill patients
  • Toxic megacolon or bowel perforation
  • Active, unrelated gastrointestinal infection
  • Pregnancy (specialist caution)
  • Severe food allergies (specialist caution)
    •
Key Interactions
  • Antibiotics (vancomycin, metronidazole, amoxicillin)
  • Proton pump inhibitors and acid suppressants (omeprazole, esomeprazole)
  • Probiotic and prebiotic supplements
  • Immunosuppressant and chemotherapy drugs (corticosteroids, calcineurin inhibitors such as tacrolimus, biologics, cytotoxic chemotherapy)
  • Bowel-cleansing preparations and recent gut surgery
    •

Risk & Side Effects

  • High: Transient gastrointestinal symptoms
    •
  • Medium: Transmission of infectious agents; aspiration and delivery-related complications
    •
  • Low: Procedural risks of endoscopic delivery; new-onset autoimmune or inflammatory conditions
    •
  • Speculative: Transfer of donor disease phenotypes; unknown long-term consequences
    •

Monitoring

Marker Target Why
Stool C. difficile toxin / PCR Negative Confirms clearance of the target infection
Fecal calprotectin <50 µg/g Tracks gut inflammation in bowel disease
C-reactive protein (CRP) <1.0 mg/L Gauges systemic inflammation and response
Complete blood count (CBC) Normal white cell count; no unexplained shifts Screens immune status and detects infection
Fasting glucose & HbA1c Glucose 70–90 mg/dL; HbA1c <5.4% Relevant when the goal is metabolic health
Comprehensive metabolic panel Within normal limits Assesses liver and kidney function, especially in cirrhosis

Cadence: Roughly 1 week and 4–8 weeks after the procedure, then as symptoms or the underlying condition dictate (e.g., every 3–6 months when managing inflammatory bowel disease)

Qualitative Assessment

  • Bowel habit normalization — resolution of diarrhea and return to regular, formed stools
  • Symptom relief — reduced bloating, cramping, and urgency
  • Energy and cognitive clarity — improved daytime energy and mental sharpness
  • Sustained remission — absence of infection recurrence or disease flare over the following months
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.